Clinical trialNCT03737643Active, not recruitingPhase 3Interventional

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

SponsorAstraZenecaEnrollment1,407Advanced Ovarian Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Carol Aghajanian
GOG
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Philipp Harter
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

214 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Austria

Research Site
Graz, Austria
Research Site
Innsbruck, Austria
Research Site
Linz, Austria
Research Site
Vienna, Austria

Belgium

Research Site
Aalst, Belgium
Research Site
Leuven, Belgium
Research Site
Namur, Belgium
Research Site
Ostend, Belgium
Research Site
Sint-Niklaas, Belgium

Brazil

Research Site
Barretos, Brazil
Research Site
Florianópolis, Brazil
Research Site
Fortaleza, Brazil
Research Site
Londrina, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil

Bulgaria

Research Site
Burgas, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Varna, Bulgaria

Canada

Research Site
Calgary, Alberta, Canada
Research Site
Barrie, Ontario, Canada
Research Site
Greater Sudbury, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Rimouski, Quebec, Canada

China

Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Bengbu, China
Research Site
Changchun, China
Research Site
Changsha, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Chongqing, China
Research Site
Dalian, China

174 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bevacizumab →Carboplatin+PaclitaxelDurvalumab →Durvalumab placeboOlaparib →Placebo olaparib

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 4 Jan 2019
Primary completion: 17 Mar 2025
Completion: 23 Dec 2026
Last update posted: 7 Jul 2026
Registered enrollment: 1,407
Registry id: NCT03737643

Cross-registrations

EU-CTR / CTIS (EudraCT)2017-004632-11

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.